CA 19-9 Response as an Early Indicator of the Effectiveness of Gemcitabine in Patients with Advanced Pancreatic Cancer

Publisher： Karger

E-ISSN： 1423-0232|75|1-2|120-126

ISSN： 0030-2414

Source： Oncology, Vol.75, Iss.1-2, 2008-09, pp. : 120-126

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Are Serial CA 19-9 Kinetics Helpful in Predicting Survival in Patients with Advanced or Metastatic Pancreatic Cancer Treated with Gemcitabine and Cisplatin?

By  

Oncology Research and Treatment, Vol. 26, Iss. 5, 2003-11 ,pp. : 462-467

Karger

Access to resources Recommend Favorite

Limited Value of CA 19-9 in Predicting Early Treatment Failure in Patients with Advanced Pancreatic Cancer

By  

Oncology, Vol. 77, Iss. 2, 2009-07 ,pp. : 140-146

Karger

Access to resources Recommend Favorite

Oral Capecitabine in Gemcitabine-Pretreated Patients with Advanced Pancreatic Cancer

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 221-227

Karger

Access to resources Recommend Favorite

Raltitrexed plus Gemcitabine (TOMGEM) in Advanced Pancreatic Cancer

By  

Oncology, Vol. 67, Iss. 5-6, 2005-02 ,pp. : 338-343

Karger

Access to resources Recommend Favorite

Pre‐treatment carbohydrate antigen 19‐9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer

By  

HPB, Vol. 17, Iss. 10, 2015-10 ,pp. : 942-952

John Wiley & Sons Inc

Access to resources Recommend Favorite